Drug Trial Radar · NCT06795022
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
304
Planned (sponsor's estimate)
Start
Mar 27, 2025
Primary completion
Jun 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Conditions
- Hepatocellular Carcinoma
Interventions
AZD9793 Intravenous (IV) monotherapyDrug
T cell-engaging antibody that targets GPC3 on tumour cells
AZD9793 Subcutaneous (SC) monotherapyDrug
T cell-engaging antibody that targets GPC3 on tumour cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of patients with adverse eventsTime frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
- The number of patients with serious adverse eventsTime frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
- The number of patients with adverse events of special interestTime frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
- The number of AEs leading to discontinuation of AZD9793Time frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
- The number of patients with dose-limiting toxicity (DLT), as defined in the protocol [Part A Dose Escalation only]Time frame: From date of first dose of study drug until the end of DLT evaluation period (up to 21, 28 or 35 days depending on dose regimen)
- Objective Response Rate (ORR) [Part B Dose Expansion only]Time frame: From first dose of study drug to progressive disease or the last evaluable assessment in the absence of disease progression whichever comes first (up to approximately 2 years)
Locations
21 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California · Withdrawn
Research Site
Los Angeles, California · Recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
Hackensack, New Jersey · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Harbin, China · Not yet recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Pokfulam, Hong Kong · Recruiting
Research Site
Shatin, Hong Kong · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Yokohama, Japan · Recruiting
Research Site
Seoul, South Korea · Not yet recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Barcelona, Spain · Not yet recruiting
Research Site
Pamplona, Spain · Not yet recruiting
Research Site
Taipei, Taiwan · Recruiting
Research Site
Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.